Desvenlafaxine Succinate Sustained-Release (DVS SR)

DRUG6 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer, Pfizer

Conditions

DepressionDepressive DisorderDepressive Disorder, MajorDiabetic Neuropathy, PainfulHealthyMajor Depressive DisorderMenopauseVasomotor System

Phase 1

Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects

CompletedNCT00727064

Wyeth is now a wholly owned subsidiary of PfizerHealthy

Start: 2008-06-30End: 2008-08-31Updated: 2010-06-02

Phase 3

Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women

CompletedNCT00369434

Wyeth is now a wholly owned subsidiary of PfizerMenopause, Vasomotor System

Start: 2006-06-30End: 2007-02-28Target: 450Updated: 2007-06-01

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

CompletedNCT00384033

PfizerDepressive Disorder, Major

Start: 2006-09-30End: 2007-09-30Updated: 2012-03-15

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

CompletedNCT00406640

Wyeth is now a wholly owned subsidiary of PfizerDepression, Depressive Disorder, Depressive Disorder, Major

Start: 2006-12-31End: 2008-10-31Updated: 2023-12-28

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

CompletedNCT00798707

PfizerMajor Depressive Disorder

Start: 2008-12-31End: 2010-04-30Updated: 2011-06-10

Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

TerminatedNCT01050218

Wyeth is now a wholly owned subsidiary of PfizerDiabetic Neuropathy, Painful

Start: 2006-07-31End: 2009-01-31Updated: 2023-12-11

Related Papers

Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials

Journal of Clinical Psychopharmacology2021-06-291 citations

Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.

2016-01-133 citations

A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d

The Primary Care Companion For CNS Disorders2015-06-0411 citations

Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis.

2015-03-267 citations

Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy.

2014-06-2327 citations

Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatients.

2013-01-0136 citations

Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.

2011-03-0110 citations